Adaptive Biotechnologies Corporation
ADPT
$2.77
$0.17016.54%
| Weiss Ratings | ADPT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | ADPT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ADPT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.95 | |||
| Price History | ADPT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -4.30% | |||
| 30-Day Total Return | -28.37% | |||
| 60-Day Total Return | -36.38% | |||
| 90-Day Total Return | -52.05% | |||
| Year to Date Total Return | -51.05% | |||
| 1-Year Total Return | -68.12% | |||
| 2-Year Total Return | -72.88% | |||
| 3-Year Total Return | -94.76% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -71.26% | |||
| 52-Week Low % Change | 14.47% | |||
| Price | ADPT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $9.08 | |||
| 52-Week Low Price | $2.28 | |||
| 52-Week Low Price (Date) | Apr 19, 2024 | |||
| 52-Week High Price (Date) | Jun 14, 2023 | |||
| Valuation | ADPT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 348.22M | |||
| Enterprise Value | 231.13M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.56 | |||
| Earnings Per Share Growth | 10.64% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 2.04 | |||
| Price/Book (Q) | 1.13 | |||
| Enterprise Value/Revenue (TTM) | 1.54 | |||
| Price | $2.34 | |||
| Enterprise Value/EBITDA (TTM) | -1.46 | |||
| Enterprise Value/EBIT | -1.30 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | ADPT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 144.90M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ADPT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 206 659 0067 | |||
| Address | 1165 Eastlake Avenue East Seattle, WA 98109 | |||
| Website | www.adaptivebiotech.com | |||
| Country | United States | |||
| Year Founded | 2009 | |||
| Profitability | ADPT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -118.39% | |||
| Profit Margin | -132.28% | |||
| Management Effectiveness | ADPT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -16.60% | |||
| Return on Equity | -- | |||
| Income Statement | ADPT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 170.28M | |||
| Total Revenue (TTM) | 170.28M | |||
| Revenue Per Share | $1.18 | |||
| Gross Profit (TTM) | 74.26M | |||
| EBITDA (TTM) | -179.38M | |||
| EBIT (TTM) | -201.61M | |||
| Net Income (TTM) | -225.25M | |||
| Net Income Avl. to Common (TTM) | -225.25M | |||
| Total Revenue Growth (Q YOY) | -17.05% | |||
| Earnings Growth (Q YOY) | -72.94% | |||
| EPS Diluted (TTM) | -1.56 | |||
| EPS Diluted Growth (Q YOY) | -70.84% | |||
| Balance Sheet | ADPT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 346.40M | |||
| Cash Per Share (Q) | $2.39 | |||
| Total Current Assets (Q) | 410.19M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 308.28M | |||
| Current Ratio (Q) | 4.660 | |||
| Book Value Per Share (Q) | $2.13 | |||
| Total Assets (Q) | 661.13M | |||
| Total Current Liabilities (Q) | 88.02M | |||
| Total Debt (Q) | 229.43M | |||
| Total Liabilities (Q) | 352.86M | |||
| Total Common Equity (Q) | 308.40M | |||
| Cash Flow | ADPT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 129.65M | |||
| Cash from Financing (TTM) | 2.25M | |||
| Net Change in Cash (TTM) | -24.43M | |||
| Levered Free Cash Flow (TTM) | -113.97M | |||
| Cash from Operations (TTM) | -156.32M | |||
